Kura Oncology, Inc. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Kura Oncology filed an 8-K on 2026-09-08 disclosing Item 5.02 regarding departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing document itself does not contain the specific details—names, titles, effective dates, severance amounts, or equity grants are not provided in the extracted text shown.
Why this rating
Executive/director changes are routine at public biotech firms. Without disclosed details (severance cost, equity impact), cannot assess materiality against $496M market cap. Likely administrative disclosure.
Extracted items
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.